Literature DB >> 24307395

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.

S Carrera1, A Buque, E Azkona, U Aresti, B Calvo, A Sancho, M Arruti, M Nuño, I Rubio, A R de Lobera, C Lopez, G L Vivanco.   

Abstract

Lung cancer remains the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) represents 85 % of all lung cancer cases and it is classified into three major subtypes: adenocarcinoma, squamous cell carcinoma and large-cell carcinoma. In the past years, molecular-targeted therapies have been developed in order to improve response, survival and quality of life in patients with advanced NSCLC. Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine-kinase inhibitors (TKIs). However, virtually all patients with initial response relapse due to acquired resistance. Better understanding the biology of these tumors and mechanisms of EGFR TKIs resistance could shed some light on research of new therapeutic options in this setting. This review aims to emphasize on EGFR involved lung cancer pathway, primary and acquired mechanisms of TKIs resistance, and discuss agents currently used in clinical development in this emerging scenario.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24307395     DOI： 10.1007/s12094-013-1143-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  85 in total

1.  New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.

Authors:  Ho Yun Lee; Kyung Soo Lee; Myung-Ju Ahn; Hye Sun Hwang; Ju Won Lee; Keunchil Park; Jin Seok Ahn; Tae Sung Kim; Chin A Yi; Myung Jin Chung
Journal:  Lung Cancer       Date:  2010-11-18       Impact factor: 5.705

Review 2.  How genetically engineered mouse tumor models provide insights into human cancers.

Authors:  Katerina Politi; William Pao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

Review 3.  Targeting phosphoinositide 3-kinase signalling in lung cancer.

Authors:  Anna Wojtalla; Alexandre Arcaro
Journal:  Crit Rev Oncol Hematol       Date:  2011-02-11       Impact factor: 6.312

4.  Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Vienna Ludovini; Fortunato Bianconi; Lorenza Pistola; Rita Chiari; Vincenzo Minotti; Renato Colella; Dario Giuffrida; Francesca Romana Tofanetti; Annamaria Siggillino; Antonella Flacco; Elisa Baldelli; Daniela Iacono; Maria Grazia Mameli; Antonio Cavaliere; Lucio Crinò
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.

Authors:  Riichiroh Maruyama; Hiroshi Wataya; Takashi Seto; Yukito Ichinose
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

8.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

9.  Architecture and membrane interactions of the EGF receptor.

Authors:  Anton Arkhipov; Yibing Shan; Rahul Das; Nicholas F Endres; Michael P Eastwood; David E Wemmer; John Kuriyan; David E Shaw
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more
  12 in total

1.  Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.

Authors:  Sung Keun Jung; Mee-Hyun Lee; Do Young Lim; Jong Eun Kim; Puja Singh; Sung-Young Lee; Chul-Ho Jeong; Tae-Gyu Lim; Hanyong Chen; Young-In Chi; Joydeb Kumar Kundu; Nam Hyouck Lee; Charles C Lee; Yong-Yeon Cho; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

2.  The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.

Authors:  Veronika Sárosi; Zoltán Balikó; Gábor Smuk; Terézia László; Mariann Szabó; István Ruzsics; Emese Mezősi
Journal:  Pathol Oncol Res       Date:  2016-04-22       Impact factor: 3.201

3.  Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.

Authors:  Toshifumi Tsukahara
Journal:  Clin Transl Oncol       Date:  2022-04-29       Impact factor: 3.340

4.  Glycyrrhetinic acid induces G1‑phase cell cycle arrest in human non‑small cell lung cancer cells through endoplasmic reticulum stress pathway.

Authors:  Jie Zhu; Meijuan Chen; Ning Chen; Aizhen Ma; Chunyan Zhu; Ruolin Zhao; Miao Jiang; Jing Zhou; Lihong Ye; Haian Fu; Xu Zhang
Journal:  Int J Oncol       Date:  2015-01-08       Impact factor: 5.650

Review 5.  Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.

Authors:  Antti P Jekunen
Journal:  J Oncol       Date:  2015-01-29       Impact factor: 4.375

6.  244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Authors:  Yi Zhang; Ke Yao; Chengcheng Shi; Yanan Jiang; Kangdong Liu; Song Zhao; Hanyong Chen; Kanamata Reddy; Chengjuan Zhang; Xiaoyu Chang; Joohyun Ryu; Ann M Bode; Ziming Dong; Zigang Dong
Journal:  Oncotarget       Date:  2015-12-29

7.  A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.

Authors:  Xiao-Fang Guo; Xiao-Fei Zhu; Hai-Ying Cao; Gen-Shen Zhong; Liang Li; Bao-Guo Deng; Ping Chen; Pei-Zhen Wang; Qing-Fang Miao; Yong-Su Zhen
Journal:  Oncotarget       Date:  2017-04-18

8.  Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.

Authors:  Shirong Zhang; Lucheng Zhu; Bing Xia; Enguo Chen; Qiong Zhao; Xiaochen Zhang; Xueqin Chen; Xufeng Chen; Shenglin Ma
Journal:  Cancer Commun (Lond)       Date:  2018-05-22

9.  The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Authors:  Donald L Smith; Jaime Acquaviva; Manuel Sequeira; John-Paul Jimenez; Chaohua Zhang; Jim Sang; Richard C Bates; David A Proia
Journal:  Target Oncol       Date:  2014-08-01       Impact factor: 4.493

Review 10.  Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Authors:  Xiaochun Wang; David Goldstein; Philip J Crowe; Jia-Lin Yang
Journal:  Onco Targets Ther       Date:  2016-09-06       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.